Multidisciplinary Overview of EGFR-Mutated NSCLC: An Expert Panel Discussion From Biomarker Testing to Managing Progressive Disease

In this podcast episode, Conor Ernst Steuer, MD, a medical oncologist; Frank Schneider, MD, a pathologist; and Elise Hitron, MSN, FNP-C, a phase I clinical trials nurse practitioner, engage in a multidisciplinary discussion of the latest management strategies for EGFR-mutated NSCLC. Topics include:Testing for targetable biomarkersTalking with patients about biomarker testingFrontline therapy for EGFR-positive NSCLCResistance to front-line osimertinibTreatment of EGFR TKI–resistant disease, including the emerging antibody–drug conjugate patritumab deruxtecanHER3 protein testingPathology considerationsNursing considerationsInterdisciplinary communicationPresenters:Conor Ernst Steuer, MDAssistant ProfessorDepartment of Medical OncologyWinship Cancer InstituteEmory UniversityAtlanta, GeorgiaFrank Schneider, MDAssociate Professor of PathologyDepartment of Pathology and Laboratory MedicineDirector, Cancer Tissue and Pathology Shared ResourceWinship Cancer InstituteEmory UniversityAtlanta, GeorgiaElise Hitron, MSN, FNP-CAdjunct InstructorSchool of NursingPhase I Clinical Trials Nurse PractitionerWinship Cancer InstituteEmory UniversityAtlanta, GeorgiaSupported by an educational grant from Daiichi Sankyo, Inc.Link to full program, including a series of short interactive virtual presentations with downloadable slidesets on EGFR-mutated advanced NSCLC, including the evolving role of HER3 in the setting of EGFR TKI resistance:https://bit.ly/3G32Jkm

There are no comments yet.

Please log in to write the first comment.